#USA #San Rafael #BioMarin #VOXZOGO #Amicus Therapeutics

BioMarin's Financial Highlights for 2025

BioMarin Pharmaceutical Inc. recently announced its financial results for the fourth quarter and the full year of 2025, showcasing a remarkable year characterized by substantial growth and significant strategic movements. The company reported a total revenue of $3.2 billion, reflecting a 13% increase year-over-year (Y/Y). This growth was primarily driven by a robust performance in enzyme therapies, which grew by 9%, and a stunning 26% growth for its leading therapy, VOXZOGO.

In the fourth quarter alone, BioMarin achieved total revenues of $875 million, marking a 17% increase from the prior year's quarter. This acceleration was buoyed by a 31% Y/Y revenue growth for VOXZOGO and a 13% growth in enzyme therapies, underscoring the consistent demand for BioMarin's innovative treatment options.

Strategic Acquisition of Amicus Therapeutics

A significant highlight from BioMarin's recent announcements is the definitive agreement to acquire Amicus Therapeutics. This acquisition is notable as it includes therapies such as Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. The deal is expected to close in the second quarter of 2026 and is projected to greatly enhance BioMarin's product offerings, enabling the company to access a wider patient base and diversify its revenue streams.

Alexander Hardy, BioMarin's President and CEO, emphasized the importance of this acquisition, stating, "The Amicus transaction represents a compelling opportunity to reach more patients around the world and further strengthen our revenue growth through the next decade." The integration of Amicus products into BioMarin’s portfolio is anticipated to significantly contribute to their ongoing growth strategy.

Financial Performance and Future Guidance

Looking ahead, BioMarin is confident that 2026 will build on the successes achieved this past year. The company has provided guidance indicating continued strong financial performance expected from both enzyme therapies and VOXZOGO. With the anticipated closing of the Amicus deal, BioMarin's revenue forecasts are optimistic, with expectations of total revenues ranging between $3.325 billion and $3.425 billion for the year.

The guidance for Non-GAAP diluted earnings per share (EPS) is projected to be between $4.95 and $5.15, reinforcing investor confidence in BioMarin's financial trajectory and commitment to innovation.

Innovations and Product Pipeline

BioMarin also reported notable advancements within its product pipeline. Key developments include:

• - The acceleration of BMN 333, a long-acting treatment for achondroplasia, which is nearing trials that may establish it as the new standard of care.
• - Progress in the VOXZOGO pipeline with five new indications being explored, which may open new therapeutic avenues.
• - Positive outcomes from the PALYNZIQ Phase 3 studies, indicating successful management of phenylketonuria (PKU) for adolescents.

The company is excited about upcoming data readouts that will support regulatory approvals and expand age labels for several therapies.

Conclusion

2025 has marked a pivotal turning point for BioMarin, with monumental revenue growth, strategic acquisitions, and innovative advancements setting the stage for a promising 2026. The company's commitment to addressing rare genetic diseases through novel therapies firmly positions it for sustained success. Investors and stakeholders alike will be watching closely as BioMarin moves forward, eager to see how these strategies unfold and how they will further benefit patients reliant on these critical therapies.